再鼎医药（09688.HK）今日盘中大涨5.59%，引发市场关注。此次涨幅主要受两大利好因素推动。
首先，根据港交所最新权益披露资料显示，FMR LLC于5月14日在场内以每股均价22.371港元增持再鼎医药197.11万股，涉资约4409.55万港元。增持后，FMR LLC持股比例由7.90%上升至8.08%，显示机构投资者对公司前景持积极态度。
其次，今日港股市场生物医药板块整体走强。三生制药大涨近15%，信达生物涨4.6%，石药集团和再鼎医药均涨近4%。这一板块性上涨也为再鼎医药股价提供了有力支撑。值得注意的是，再鼎医药在美股市场上一交易日也表现亮眼，收涨超6%，显示出投资者对该公司的持续看好。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.